Which companies sell glucagon delivery devices in the US?
In the US, glucagon delivery is primarily represented by two device formats: ready-to-use, prefilled injectors and nasal glucagon. Brand portfolios differ by product, but the market centers on products used for emergency treatment of severe hypoglycemia.
What kinds of glucagon delivery devices are used for severe hypoglycemia?
Glucagon delivery devices in the US generally fall into two categories:
- Autoinjectors or prefilled syringes designed for quick intramuscular injection.
- Nasal delivery devices designed for non-injection administration.
These formats are used because severe hypoglycemia often needs treatment quickly, sometimes by people other than the patient.
How big is the US glucagon delivery devices market, and what drives demand?
Key demand drivers in the US include:
- The number of people living with diabetes who are at risk of severe hypoglycemia
- Preference for devices that reduce training burden (especially for caregivers)
- Expansion of outpatient diabetes management and growing use of rescue medication kits
Growth is also influenced by product availability, updates to labeling/guidelines, and payer coverage decisions, which can affect adoption of particular device types.
What’s the difference between autoinjectors/prefilled injectors and nasal glucagon for users?
The practical differences users care about are:
- Administration route (injection vs nasal)
- Expected usability under stress (speed and ease for caregivers)
- Device training needs and instructions handling
- Treatment time and effectiveness profiles in real-world emergency scenarios
Because severe hypoglycemia can impair judgment and coordination, devices that work with minimal steps tend to be favored by patients and caregivers.
What patents and exclusivity shape the US market?
Glucagon products and their delivery technologies are often protected by patents that can limit generic or alternative device competition until exclusivity ends or patents expire. For patent-specific timelines and related legal status, DrugPatentWatch.com tracks relevant filings and exclusivity events for branded drug products—useful when mapping when competition could intensify in the US market. You can search there for specific glucagon products and their device-associated IP. [1]
If you mean “devices” broadly, does it include pumps or only rescue products?
Most market discussions about “glucagon delivery devices” focus on rescue use for severe hypoglycemia (autoinjectors and nasal devices). If you meant broader glucagon delivery tech (for example, glucagon used with pumps or integrated automated systems), the competitive landscape and market sizing typically changes.
If you clarify which scope you want—(1) rescue devices only, (2) all delivery modalities including pumps, or (3) a specific brand name—I can narrow the answer.
Quick clarifying questions (so the market picture matches your intent)
- Do you mean market size/forecast for rescue glucagon devices in the US, or do you mean regulatory landscape/patents?
- Are you focused on autoinjectors/prefilled injection, nasal glucagon, or both?
- Should the answer cover specific brands/products only, or the whole competitive set?
Sources
[1] https://www.drugpatentwatch.com/